{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:12:31Z","timestamp":1757704351128,"version":"3.35.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,9,6]],"date-time":"2008-09-06T00:00:00Z","timestamp":1220659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s10741-008-9110-1","type":"journal-article","created":{"date-parts":[[2008,9,5]],"date-time":"2008-09-05T15:28:34Z","timestamp":1220628514000},"page":"65-73","source":"Crossref","is-referenced-by-count":12,"title":["Treatment options for hyponatremia in heart failure"],"prefix":"10.1007","volume":"14","author":[{"given":"Steven R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,9,6]]},"reference":[{"key":"9110_CR1","volume-title":"Heart disease and stroke statistics\u20142004 update","author":"American Heart Association","year":"2003","unstructured":"American Heart Association (2003) Heart disease and stroke statistics\u20142004 update. American Heart Association, Dallas, Texas"},{"issue":"suppl 7","key":"9110_CR2","first-page":"S21","volume":"4","author":"GC Fonarow","year":"2003","unstructured":"Fonarow GC, ADHERE Scientific Advisory Committee (2003) The acute decompensated heart failure national registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 4(suppl 7):S21\u2013S30","journal-title":"Rev Cardiovasc Med"},{"key":"9110_CR3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","volume":"287","author":"MS Cuffe","year":"2002","unstructured":"Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS et al (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. J Am Med Assoc 287:1541\u20131547. doi: 10.1001\/jama.287.12.1541","journal-title":"J Am Med Assoc"},{"key":"9110_CR4","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/archinte.1996.00440150068007","volume":"156","author":"MH Chin","year":"1996","unstructured":"Chin MH, Goldman L (1996) Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 156:1814\u20131820. doi: 10.1001\/archinte.156.16.1814","journal-title":"Arch Intern Med"},{"key":"9110_CR5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0953-6205(02)00086-9","volume":"13","author":"PS Wong","year":"2002","unstructured":"Wong PS, Davidsson GK, Timeyin J, Warren A, Watson DJ, Vincent R et al (2002) Heart failure in patients admitted to hospital: mortality is still high. Eur J Intern Med 13:304\u2013310. doi: 10.1016\/S0953-6205(02)00086-9","journal-title":"Eur J Intern Med"},{"key":"9110_CR6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000073931","volume":"100","author":"M-C Chen","year":"2003","unstructured":"Chen M-C, Chang H-W, Cheng C-I, Chen Y-H, Chai H-T (2003) Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology 100:136\u2013142. doi: 10.1159\/000073931","journal-title":"Cardiology"},{"key":"9110_CR7","first-page":"715","volume":"5","author":"HM Krumholz","year":"1999","unstructured":"Krumholz HM, Chen Y-T, Bradford WD, Cerese J (1999) Variations and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. Am J Manag Care 5:715\u2013723","journal-title":"Am J Manag Care"},{"key":"9110_CR8","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.290.19.2581","volume":"290","author":"DS Lee","year":"2003","unstructured":"Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV (2003) Predicting mortality among patients hospitalized for heart failure. Derivation and validation of a clinical model. J Am Med Assoc 290:2581\u20132587. doi: 10.1001\/jama.290.19.2581","journal-title":"J Am Med Assoc"},{"key":"9110_CR9","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000165065.82609.3D","volume":"111","author":"L Klein","year":"2005","unstructured":"Klein L, O\u2019Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM et al (2005) Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) study. Circulation 111:2454\u20132460. doi: 10.1161\/01.CIR.0000165065.82609.3D","journal-title":"Circulation"},{"key":"9110_CR10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.73.2.257","volume":"73","author":"WH Lee","year":"1986","unstructured":"Lee WH, Packer M (1986) Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73:257\u2013267","journal-title":"Circulation"},{"key":"9110_CR11","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0735-1097(02)02490-7","volume":"40","author":"MT Kearney","year":"2002","unstructured":"Kearney MT, Fox KAA, Lee AJ, Prescott RJ, Shah AM, Batin PD et al (2002) Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol 40:1801\u20131808. doi: 10.1016\/S0735-1097(02)02490-7","journal-title":"J Am Coll Cardiol"},{"key":"9110_CR12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM198107303050506","volume":"305","author":"VL Szatalowicz","year":"1981","unstructured":"Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW (1981) Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305:263\u2013266","journal-title":"N Engl J Med"},{"key":"9110_CR13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(82)90576-9","volume":"72","author":"GAJ Riegger","year":"1982","unstructured":"Riegger GAJ, Lebau G, Kochsiek K (1982) Antidiuretic hormone in congestive heart failure. Am J Med 72:49\u201352. doi: 10.1016\/0002-9343(82)90576-9","journal-title":"Am J Med"},{"key":"9110_CR14","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","volume":"82","author":"GS Francis","year":"1990","unstructured":"Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C-S et al (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 82:1724\u20131729","journal-title":"Circulation"},{"key":"9110_CR15","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","volume":"1","author":"SR Goldsmith","year":"1983","unstructured":"Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN (1983) Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1:1385\u20131390","journal-title":"J Am Coll Cardiol"},{"key":"9110_CR16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0002-9149(86)90065-2","volume":"58","author":"SR Goldsmith","year":"1986","unstructured":"Goldsmith SR, Francis GS, Cowley AW Jr (1986) Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 58:295\u2013299. doi: 10.1016\/0002-9149(86)90065-2","journal-title":"Am J Cardiol"},{"key":"9110_CR17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem-58-4-599","volume":"58","author":"W Pruszczynski","year":"1984","unstructured":"Pruszczynski W, Vahanian A, Ardaillou R, Acar J (1984) Role of antidiuretic hormone in impaired water excretion of patients with congestive heart failure. J Clin Endocrinol Metab 58:599\u2013605","journal-title":"J Clin Endocrinol Metab"},{"key":"9110_CR18","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/ki.1986.126","volume":"29","author":"DG Bichet","year":"1986","unstructured":"Bichet DG, Kortas C, Mettauer B, Manzini C, Marc-Aur\u00e8le J, Rouleau JL et al (1986) Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int 29:1188\u20131196. doi: 10.1038\/ki.1986.126","journal-title":"Kidney Int"},{"key":"9110_CR19","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Gattis WA, O\u2019Connor CM, Adams KF, Elkayam U, Barbagelata A et al (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. J Am Med Assoc 291:1963\u20131971. doi: 10.1001\/jama.291.16.1963","journal-title":"J Am Med Assoc"},{"key":"9110_CR20","doi-asserted-by":"crossref","first-page":"71.e1","DOI":"10.1016\/j.amjmed.2005.09.026","volume":"119","author":"B Renneboog","year":"2006","unstructured":"Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G (2006) Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 119:71.e1\u201371.e8","journal-title":"Am J Med"},{"key":"9110_CR21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1067\/mhj.2003.166","volume":"145","author":"G Licata","year":"2003","unstructured":"Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G et al (2003) Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J 145:459\u2013466. doi: 10.1067\/mhj.2003.166","journal-title":"Am Heart J"},{"key":"9110_CR22","first-page":"389","volume-title":"Vasopressin: cellular and integrative functions","author":"SR Goldsmith","year":"1988","unstructured":"Goldsmith SR (1988) Baroreflex control of vasopressin secretion in normal humans. In: Cowley AW, Liard J-F, Ausiello DA (eds) Vasopressin: cellular and integrative functions. Raven Press, New York, NY, pp 389\u2013397"},{"key":"9110_CR23","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1126\/science.3006248","volume":"231","author":"MA Dillingham","year":"1986","unstructured":"Dillingham MA, Anderson RJ (1986) Inhibition of vasopressin action by atrial natriuretic factor. Science 231:1572\u20131573. doi: 10.1126\/science.3006248","journal-title":"Science"},{"key":"9110_CR24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1071-9164(99)91339-8","volume":"5","author":"SR Goldsmith","year":"1999","unstructured":"Goldsmith SR (1999) Vasopressin: a therapeutic target in congestive heart failure? J Card Fail 5:347\u2013356. doi: 10.1016\/S1071-9164(99)91339-8","journal-title":"J Card Fail"},{"key":"9110_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0290001","volume":"29","author":"JG Verbalis","year":"2002","unstructured":"Verbalis JG (2002) Vasopressin V2 receptor antagonists. J Mol Endocrinol 29:1\u20139. doi: 10.1677\/jme.0.0290001","journal-title":"J Mol Endocrinol"},{"key":"9110_CR26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1681\/ASN.V103647","volume":"10","author":"S Nielsen","year":"1999","unstructured":"Nielsen S, Kwon TH, Christensen BM, Promeneur D, Fr\u00f8kiaer J, Marples D (1999) Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 10:647\u2013663","journal-title":"J Am Soc Nephrol"},{"key":"9110_CR27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1172\/JCI114182","volume":"84","author":"AT Hirsch","year":"1989","unstructured":"Hirsch AT, Dzau VJ, Majzoub JA, Creager MA (1989) Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. J Clin Invest 84:418\u2013426. doi: 10.1172\/JCI114182","journal-title":"J Clin Invest"},{"key":"9110_CR28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI9516","volume":"106","author":"JE Kaufmann","year":"2000","unstructured":"Kaufmann JE, Oksche A, Wollheim CB, G\u00fcnther G, Rosenthal W, Vishcer UM (2000) Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 106:107\u2013116. doi: 10.1172\/JCI9516","journal-title":"J Clin Invest"},{"key":"9110_CR29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1172\/JCI200419656","volume":"113","author":"A Tanoue","year":"2004","unstructured":"Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu T-A et al (2004) The vasopressin 1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 113:302\u2013309","journal-title":"J Clin Invest"},{"key":"9110_CR30","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0735-1097(86)80333-3","volume":"7","author":"MA Creager","year":"1986","unstructured":"Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H (1986) Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 7:758\u2013765","journal-title":"J Am Coll Cardiol"},{"key":"9110_CR31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0735-1097(86)80417-X","volume":"8","author":"SR Goldsmith","year":"1986","unstructured":"Goldsmith SR, Francis GS, Cowley AW Jr, Goldenberg IF, Cohn JN (1986) Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 8:779\u2013783","journal-title":"J Am Coll Cardiol"},{"key":"9110_CR32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.RES.69.1.239","volume":"69","author":"YJ Xu","year":"1991","unstructured":"Xu YJ, Gopalakrishnan V (1991) Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ Res 69:239\u2013245","journal-title":"Circ Res"},{"key":"9110_CR33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-2999(99)00775-X","volume":"391","author":"Y Nakamura","year":"2000","unstructured":"Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K (2000) Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol 391:39\u201348. doi: 10.1016\/S0014-2999(99)00775-X","journal-title":"Eur J Pharmacol"},{"key":"9110_CR34","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T et al (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287:860\u2013867","journal-title":"J Pharmacol Exp Ther"},{"key":"9110_CR35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/978-1-4615-4871-3_55","volume":"449","author":"PS Chan","year":"1998","unstructured":"Chan PS, Coupet J, Pack HC, Lai F, Hartupee D, Cervoni P et al (1998) VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 449:439\u2013443","journal-title":"Adv Exp Med Biol"},{"key":"9110_CR36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-3565(24)36784-9","volume":"282","author":"A Tahara","year":"1997","unstructured":"Tahara A, Tomura Y, Wada K-I, Kusayama T, Tsukada J, Takanashi M et al (1997) Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in\u00a0vitro and in\u00a0vivo. J Pharmacol Exp Ther 282:301\u2013308","journal-title":"J Pharmacol Exp Ther"},{"key":"9110_CR37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1440-1681.1999.03045.x","volume":"26","author":"Y Tomura","year":"1999","unstructured":"Tomura Y, Tahara A, Tsukada J, Yatsu T, Uchida W, Iizumi Y et al (1999) Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats. Clin Exp Pharmacol Physiol 26:399\u2013403. doi: 10.1046\/j.1440-1681.1999.03045.x","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"9110_CR38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(99)00530-0","volume":"381","author":"J Risvanis","year":"1999","unstructured":"Risvanis J, Naitoh M, Johnston CI, Burrell LM (1999) In\u00a0vivo and in\u00a0vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat. Eur J Pharmacol 381:23\u201330. doi: 10.1016\/S0014-2999(99)00530-0","journal-title":"Eur J Pharmacol"},{"key":"9110_CR39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0014-2999(96)00940-5","volume":"321","author":"T Yatsu","year":"1997","unstructured":"Yatsu T, Tomura Y, Tahara A, Wada K-I, Tsukada J, Uchida W et al (1997) Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. Eur J Pharmacol 321:225\u2013230. doi: 10.1016\/S0014-2999(96)00940-5","journal-title":"Eur J Pharmacol"},{"key":"9110_CR40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1527-3466.2001.tb00065.x","volume":"19","author":"C Serradeil-Le Gal","year":"2001","unstructured":"Serradeil-Le Gal C (2001) An overview of SR121463, a selective non-peptide vasopressin V2 receptor antagonist. Cardiovasc Drug Rev 19:201\u2013214","journal-title":"Cardiovasc Drug Rev"},{"key":"9110_CR41","first-page":"H2245","volume":"267","author":"M Naitoh","year":"1994","unstructured":"Naitoh M, Suzuki H, Murakami M, Matsumoto A, Arakawa K, Ichihara A et al (1994) Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 267:H2245\u2013H2254","journal-title":"Am J Physiol"},{"key":"9110_CR42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00005344-199602000-00015","volume":"27","author":"T Nishikimi","year":"1996","unstructured":"Nishikimi T, Kawano Y, Saito Y, Matsuoka H (1996) Effect of long-term treatment with selective V1 and V2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 27:275\u2013282. doi: 10.1097\/00005344-199602000-00015","journal-title":"J Cardiovasc Pharmacol"},{"key":"9110_CR43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-2999(99)00379-9","volume":"376","author":"T Yatsu","year":"1999","unstructured":"Yatsu T, Tomura Y, Tahara A, Wada K-I, Kusayama T, Tsukada J et al (1999) Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 376:239\u2013246. doi: 10.1016\/S0014-2999(99)00379-9","journal-title":"Eur J Pharmacol"},{"key":"9110_CR44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0014-2999(02)02101-5","volume":"450","author":"K Wada","year":"2002","unstructured":"Wada K, Tahara A, Arai Y, Aoki M, Tomura Y, Tsukada J et al (2002) Effect of the vasopressin antagonist conivaptan in rats with heart failure following myocardial infarction. Eur J Pharmacol 450:169\u2013177. doi: 10.1016\/S0014-2999(02)02101-5","journal-title":"Eur J Pharmacol"},{"key":"9110_CR45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0008-6363(02)00244-4","volume":"54","author":"M Naitoh","year":"2002","unstructured":"Naitoh M, Risvanis J, Balding LC, Johnston CI, Burrell LM (2002) Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition. Cardiovasc Res 54:51\u201357. doi: 10.1016\/S0008-6363(02)00244-4","journal-title":"Cardiovasc Res"},{"key":"9110_CR46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000106456","volume":"27","author":"D Zeltser","year":"2007","unstructured":"Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N, Conivaptan Study Group (2007) Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 27:447\u2013457. doi: 10.1159\/000106456","journal-title":"Am J Nephrol"},{"key":"9110_CR47","doi-asserted-by":"crossref","unstructured":"Annane D, Decaux G, Smith N (2008) Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci (in press)","DOI":"10.1097\/MAJ.0b013e31817b8148"},{"key":"9110_CR48","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/jc.2005-2287","volume":"91","author":"JK Ghali","year":"2006","unstructured":"Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA et al (2006) Efficacy and safety of oral conivaptan: a V1A\/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91:2145\u20132152. doi: 10.1210\/jc.2005-2287","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl A","key":"9110_CR49","first-page":"62A","volume":"47","author":"JK Ghali","year":"2006","unstructured":"Ghali JK, Verbalis JG, Gross P, Long WA, Smith N (2006) Conivaptan, a novel arginine vasopressin antagonist, increased serum sodium concentration in patients with heart failure and euvolemic or hypervolemic hyponatremia. J Am Coll Cardiol 47(suppl A):62A","journal-title":"J Am Coll Cardiol"},{"key":"9110_CR50","doi-asserted-by":"crossref","unstructured":"Ghali JK, Yan B, McNutt B (2008) Conivaptan, a vasopressin-receptor antagonist, for the treatment of hyponatremia in patients with and without underlying heart failure. Abstract to be presented at: heart failure society of America 12th annual scientific meeting, Toronto, Canada, 21 September 2008","DOI":"10.1016\/j.cardfail.2008.06.199"},{"key":"9110_CR51","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2003.50021","volume":"37","author":"F Wong","year":"2003","unstructured":"Wong F (2003) A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37:182\u2013191. doi: 10.1053\/jhep.2003.50021","journal-title":"Hepatology"},{"key":"9110_CR52","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355:2099\u20132112. doi: 10.1056\/NEJMoa065181","journal-title":"N Engl J Med"},{"key":"9110_CR53","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K et al (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. J Am Med Assoc 297:1319\u20131331. doi: 10.1001\/jama.297.12.1319","journal-title":"J Am Med Assoc"},{"key":"9110_CR54","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0002-9343(98)00365-9","volume":"106","author":"BK Kr\u00e4mer","year":"1999","unstructured":"Kr\u00e4mer BK, Schweda F, Riegger GAJ (1999) Diuretic treatment and diuretic resistance in heart failure. Am J Med 106:90\u201396. doi: 10.1016\/S0002-9343(98)00365-9","journal-title":"Am J Med"},{"key":"9110_CR55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0002-9629(15)40676-7","volume":"319","author":"A Greenberg","year":"2000","unstructured":"Greenberg A (2000) Diuretic complications. Am J Med Sci 319:10\u201324. doi: 10.1097\/00000441-200001000-00002","journal-title":"Am J Med Sci"},{"key":"9110_CR56","first-page":"1308","volume":"44","author":"KT Weber","year":"2004","unstructured":"Weber KT (2004) Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. J Am Coll Cardiol 44:1308\u20131310","journal-title":"J Am Coll Cardiol"},{"key":"9110_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","volume":"103","author":"GS Francis","year":"1985","unstructured":"Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine B, Cohn JN (1985) Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med 103:1\u20136","journal-title":"Ann Intern Med"},{"key":"9110_CR58","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1042\/cs0590443","volume":"59","author":"H Ikram","year":"1980","unstructured":"Ikram H, Chan W, Espiner EA, Nicholls MG (1980) Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci 59:443\u2013449","journal-title":"Clin Sci"},{"key":"9110_CR59","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jacc.2004.04.059","volume":"44","author":"JM McCurley","year":"2004","unstructured":"McCurley JM, Hanlon SU, Wei SK, Wedam EF, Michalski M, Haigney MC (2004) Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 44:1301\u20131307. doi: 10.1016\/j.jacc.2004.04.059","journal-title":"J Am Coll Cardiol"},{"key":"9110_CR60","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","volume":"42","author":"M Domanski","year":"2003","unstructured":"Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E (2003) Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 42:705\u2013708. doi: 10.1016\/S0735-1097(03)00765-4","journal-title":"J Am Coll Cardiol"},{"key":"9110_CR61","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(24)35289-9","volume":"292","author":"T Hirano","year":"2000","unstructured":"Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T (2000) Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292:288\u2013294","journal-title":"J Pharmacol Exp Ther"},{"key":"9110_CR62","doi-asserted-by":"crossref","unstructured":"Goldsmith SR, Elkayam U, Haught WH, Barve A, He W (2008) Efficacy and safety of the vasopressin V1A\/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail (in press)","DOI":"10.1016\/j.cardfail.2008.06.003"},{"key":"9110_CR63","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","volume":"104","author":"JE Udelson","year":"2001","unstructured":"Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I et al (2001) Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104:2417\u20132423. doi: 10.1161\/hc4501.099313","journal-title":"Circulation"},{"key":"9110_CR64","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C et al (2006) Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290:F273\u2013F278. doi: 10.1152\/ajprenal.00195.2005","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-008-9110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-008-9110-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-008-9110-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T21:07:50Z","timestamp":1738357670000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-008-9110-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,6]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["9110"],"URL":"https:\/\/doi.org\/10.1007\/s10741-008-9110-1","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"type":"print","value":"1382-4147"},{"type":"electronic","value":"1573-7322"}],"subject":[],"published":{"date-parts":[[2008,9,6]]}}}